Method for treating abdominal discomfort

Abstract

Disclosed is a novel use of a chloride channel opener, especially a prostaglandin compound for the treatment of abdominal discomfort. Further disclosed is a novel use of a chloride channel opener, especially a prostaglandin compound for the treatment of functional gastrointestinal disorders.

1 . A method for treating functional gastrointestinal disorders in a mammalian subject, which comprises administration of an effective amount of a chloride channel opener to the subject. 
     
     
         2 . The method as described in  claim 1 , wherein said chloride channel opener is a ClC channel opener. 
     
     
         3 . The method as described in  claim 2 , wherein said ClC channel opener is a ClC-2 channel opener. 
     
     
         4 . The method as described in  claim 1 , wherein said chloride channel opener is a prostaglandin compound. 
     
     
         5 . The method as described in  claim 4 , wherein said prostaglandin compound is a compound as shown by the following general formula (I) 
       
         
           
           
               
               
           
         
         wherein L, M and N are hydrogen atom, hydroxy, halogen atom, lower alkyl, hydroxy(lower)alkyl, lower alkanoyloxy or oxo, wherein at least one of L and M is a group other than hydrogen, and the five-membered ring may have at least one double bond; 
         A is —CH 3 , or —CH 2 OH, —COCH 2 OH, —COOH or a functional derivative thereof; 
         B is single bond, —CH 2 —CH 2 —, —CH═CH—, —C≡C—, —CH 2 —CH 2 —CH 2 —, —CH═CH—CH 2 —, —CH 2 —CH═CH—, —C≡C—CH 2 — or —CH 2 —C≡C—; 
         Z is 
       
       
         
           
           
               
               
           
         
       
       or single bond
 wherein R 4  and R 5  are hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or hydroxy(lower)alkyl, wherein R 4  and R 5  are not hydroxy and lower alkoxy at the same time; 
 R 1  is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, alkyl, hydroxy, oxo, aryl or heterocyclic group, and at least one of carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur; and 
 Ra is a saturated or unsaturated lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, oxo, hydroxy, lower alkyl, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, cyclo(lower)alkyloxy, aryl, aryloxy, heterocyclic group or heterocyclic-oxy group; lower alkoxy; lower alkanoyloxy; cyclo(lower)alkyl; cyclo(lower)alkyloxy; aryl; aryloxy; heterocyclic group; heterocyclic-oxy. 
 
     
     
         6 . The method as described in  claim 4 , wherein said prostaglandin compound is a 16-mono or dihalogen-prostaglandin compound. 
     
     
         7 . The method as described in  claim 4 , wherein said prostaglandin compound is a 13,14-dihydro-16-mono or dihalogen-prostaglandin compound. 
     
     
         8 . The method as described in  claim 4 , wherein said prostaglandin compound is a 13,14-dihydro-15-keto-16-mono or dihalogen-prostaglandin compound. 
     
     
         9 . The method as described in  claim 4 , wherein said prostaglandin compound is a 13,14-dihydro-16-mono or difluoro-prostaglandin compound. 
     
     
         10 . The method as described in  claim 4 , wherein said prostaglandin compound is a 13,14-dihydro-15-keto-16-mono or difluoro-prostaglandin compound. 
     
     
         11 . The method as described in  claim 4 , wherein said prostaglandin compound is a 13,14-dihydro-16-mono or dihalogen-prostaglandin E compound. 
     
     
         12 . The method as described in  claim 4 , wherein said prostaglandin compound is a 13,14-dihydro-15-keto-16-mono or dihalogen-prostaglandin E compound. 
     
     
         13 . The method as described in  claim 4 , wherein said prostaglandin compound is a 13,14-dihydro-16,16-difluoro-prostaglandin E 1  compound. 
     
     
         14 . The method as described in  claim 4 , wherein said prostaglandin compound is a 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E 1  compound or 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E 1  compound. 
     
     
         15 . The method as described in  claim 4 , wherein said functional gastrointestinal disorders comprise irritable bowel syndrome and/or functional dyspepsia. 
     
     
         16 . The method as described in  claim 4 , which comprises systemic administration 1-4 times per day or continuous administration at the amount of 0.01-100 μg per day. 
     
     
         17 . The method as described in  claim 4 , wherein the administration is at the amount of 0.1-10 μg/kg per day.